Methods: A total of 1800 consecutive patients who underwent CABG between October 2007 and October 2010 in our clinic were retrospectively analyzed. A total of 61 patients (44 males, 17 females; mean age 63±10 years; range 42 to 79 years) were enrolled including 21 of them without clopidogrel, 20 with clopidogrel 300 mg and 20 with clopidogrel 600 mg due to ACS. All of the patients underwent emergent angiography due to ACS. All of them underwent CABG surgery within minimum two hours and maximum 18 hours. Postoperative bleeding, reoperation due to bleeding, length of stay in the intensive care unit (ICU) and hospital and early-term mortality of the patients were compared.
Results: No significant difference in the amount of bleeding was observed between the postoperative chest tube drainages of patients who received clopidogrel 300 mg compared to the patients who received no clopidogrel therapy (450cc, 400cc, respectively, p>0.05). The amount of bleeding was significantly higher in patients who received clopidogrel 600 mg compared to patients who received no clopidogrel therapy (625cc, 400cc, respectively p<0.005). There was no significant difference between patients taking clopidogrel 300 mg and 600 mg (respectively, 450cc, 625cc p>0.05). The length of stay in the ICU and hospital were similar in all three groups.
Conclusion: Patients who received loading dose of clopidogrel 300 mg due to ACS may undergo CABG surgery after emergent angiography. Postoperative bleeding may not be a critical challenge in these patients. However patients who receive loading dose of clopidogrel 600 mg are at high risk for postoperative bleeding and complications compared to patients not receiving clopidogrel.